IQVIA Holdings reports Q1 2026 results on May 5 with the Street's consensus price target sitting nearly 45% above the current share price — a gap that either signals deep undervaluation or a target deck that hasn't fully adjusted to a changed growth outlook.
The analyst picture is the central tension heading into the print. Most firms cut targets sharply after Q4 results in early February — JP Morgan to $225, UBS to $240, Jefferies to $255 — yet all maintained positive ratings. The more telling move came from Evercore ISI on April 8, which trimmed its target further to $185 while keeping an Outperform, putting it closest to where the stock actually trades. The consensus mean at $229.60 implies the bulk of the Street still sees a material recovery, but IQV has spent the past month drifting lower — down 7.5% over 30 days to $157.77 — suggesting investors aren't yet ready to pay for that recovery.
The bear case centres on a deceleration that is hard to ignore. Constant-currency revenue growth has stepped down from 6.8% to 3.8%, and the company's own commentary has flagged discomfort with any 2026 growth trajectory below 5%. Rising interest-rate pressure compounds the earnings risk. Bulls counter with pockets of genuine momentum: the FSP, Real World Evidence, and CSMS segments all grew year-over-year in Q3, client decision timelines are improving, and R&DS is guided to grow above 4% on a constant-currency basis. The debate, at its core, is whether those green shoots are enough to re-accelerate the top line to a level that justifies rerating.
Short positioning offers little signal either way. Short interest at 2.4% of free float is modest, and has actually fallen roughly 7.6% over the past month. Borrow conditions are exceptionally easy — cost to borrow is just 0.35%, down almost 20% over the same period, and the lending pool is far from strained. Options positioning is likewise unremarkable: the put/call ratio at 0.78 is marginally below its 20-day average of 0.80, showing no unusual demand for downside protection. The ORTEX short score has drifted lower from 34 to 32 over the past two weeks, consistent with short sellers reducing rather than adding pressure.
The institutional base remains deep — Vanguard and BlackRock together hold roughly 20% of shares, with JP Morgan Asset Management adding 682,000 shares in the most recent quarter. Insider activity tells a more cautious story: CEO Ari Bousbib and CFO Ron Bruehlman both sold shares in February at prices well above current levels, and net insider activity over 90 days is skewed to the sell side. The Q1 print is therefore less a question about short-term positioning and more a test of whether the growth re-acceleration story the Street is still pricing in has actually begun.
See the live data behind this article on ORTEX.
Open IQV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
